Real-time PCR analysis of PML-RARα in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy

Annals of Oncology

Volumn 17, Issue 10, 2006, Pages 1553-1559

  Ghaffari, S H ^a   Rostami, S ^a   Bashash, D ^a   Alimoghaddam, K ^a   Ghavamzadeh, A ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

APL; Arsenic trioxide; MRD; PML RAR ; RQ PCR

Indexed keywords

ARSENIC TRIOXIDE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYBRID PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT MONITORING; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

EID: 33749623848     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl150     Document Type: Article

References (31)

1. Tallman MS, Andersen JW, Schiffer CA et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-1028.
2. Soignet S, Fleischauer A, Polyak T et al. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study. Cancer Chemother Pharmacol 1997; 40 (Suppl): S25-S29.
3. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group. Blood 1999; 94: 1192-1200.
4. Slack JL, Waxman S, Tricot G et al. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist 2002; 7: 1-13.
5. Chen G-Q, Shi XG, Tang W et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
6. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
7. Soignet SL, Maslak P, Wang ZG et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.
8. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860.
9. Estey EH, Giles FJ, Beran M et al. Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222-4224.
10. Jing y, Wang L, Xia L et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264-269.
11. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17: 131-134.
12. Tobal K, Moore H, Macheta M et al. Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARalpha transcripts with a sensitive competitive RT-PCR method. Leukemia 2001; 15: 1060-1065.
13. Cassinat B, Zassadowski F, Balitrand N et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000; 14: 324-328.
14. Visani G, Buonamici S, Malagola M et al. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: Real time quantification of minimal residual disease. A pilot study. Leukemia 2001; 15: 1696-1700.
15. Slack JL, Bi W, Livak KJ et al. Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction. J Mol Diagn 2001; 3/4: 141-149.
16. Gallagher RE, Yeap BY, Bi W et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101: 2521-2528.
17. Schnitter S, Weisser M, Schoch C et al. New score predicting for prognosis in PML-RAR, AML1-ETO, or CBFB-MYH11-positive acute myeloid leukemia based on quantification of fussion transcripts. Blood 2003; 102: 2746-2755.
18. Gu BW, Hu J, Xu L et al. Feasibility and clinical significance of real-time quantitative RT-PCR assay of PML-RARalpha fusion transcript in patients with acute promyelocytic leukemia. Hematol J 2001; 2: 330-340.
19. Shen ZX, Shi ZZ, Fang J et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. PNAS 2004; 101: 5328-5335.
20. Biondi A, Rambaldi A, Alcalay M et al. RARA gene rearrangements as a genetic marker for diagnosis and monitoring in APL. Blood 1991; 77: 1418-1422.
21. Roche Molecular Biochemicals. The fastest way to detect and quantify PML-RARA fusion transcripts while performing hematology research. Biochemica 2002; 4: 8.
22. Seale JR, Varma S, Swirsky DM et al. Quantification of PML-RAR alpha transcripts in acute promyelocytic leukaemia: Explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon. Br J Haematol 1996; 95: 95-101.
23. Gabert J, Beillard E, van der Velden et al. Standardization and quality control studies of 'real time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
24. Mandelli F, Diverio D, Avvisati G et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell' Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014-1021.
25. Burnett AK, Grimwade D, Solomon E et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial. Blood 1999; 93: 4131-4143.
26. Devaraj PE, Foroni L, Prentice HG et al. Relapse of acute promyelocytic leukemia follows serial negative RT-PCR assays: A cautionary tale. Leuk Res 1996; 20: 733-737.
27. Lo Coco F, Diverio D, Avvisati G et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225-2229.
28. Tobal K, Liu Yin JA. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL. Leukemia 1998; 12: 1349-1354.
29. Reiter A, Lengfelder E, Grimwade D. Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia. Acta Haematol 2004; 112: 55-67.
30. Grimwade D, and Lococo F. Acute promyelocytic leukemia: A model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002; 16: 1959-1973.
31. Grimwade D. The significance of minimal residual disease in patients with t(15;17). Best Practice Research Haematol 2002; 15: 137-158.